Property update — November–December 2013: landlord and tenant
Here is another case involving a tenant who stayed on in commercial premises after a ‘contracted-out’ lease had expired. But, unusually, it was the tenant who got caught out by the consequences.
Despite its title, Barclays Wealth Trustees (Jersey) Ltd v Erimus Housing Ltd is not a housing case. The demised premises were used by the housing association as its head office. The tenancy created by the lease had been ‘contracted out’ of the Landlord and Tenant Act 1954, meaning that the tenant had no statutory right to remain in the premises beyond the contractual expiry date.
When the tenant did stay on in occupation — for almost three years — the court was asked to rule on the basis of the tenant’s occupation…
If you are registered and logged in to the site, click on the link below to read the rest of the Wragge & Co briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.